- This event has passed.
Health Economics & Reimbursement 101: Dispelling Common Market Access Myths
June 16 @ 6:00 pm - 7:30 pm UTC-7$10 – $15
Obtaining regulatory approval is a hurdle that, once cleared, allows medtech innovators and manufacturers to sell their product, but doesn’t give payers a single reason to cover it. Ensuring that the product or service is utilized to its fullest potential relies on obtaining reimbursement. Payers often require evidence supporting a strong return on investment (in terms of cost savings, lower readmission rates, and improved outcomes) to adopt a new technology and offer reimbursement to providers and patients. While the US reimbursement system is undergoing a transition (transitioning from paying for volume to paying for value), many myths abound with respect to reimbursement and market access for medical technologies. Perpetuating these myths can lead to market failure. In this seminar, these myths will be explored and dispelled, and the importance of health economics in helping clients to develop data-driven solutions and analysis frameworks that articulate their value story in support of coverage, coding and reimbursement (and magnify studies designed to support regulatory approval to serve a dual market access purpose) will be discussed
Greg Schneider, MBA is a healthcare strategy and innovation leader who creates and manages integrated frameworks of payer, policy and advocacy strategies to maximize market access, patient access, product differentiation and reimbursement. He develops and executes complex healthcare programs across the care continuum to improve outcomes, decrease costs, enhance patient, caregiver and provider satisfaction, and has completed market access, payer, and reimbursement activities for start-up companies and beyond across a breadth of indications and device areas. He serves as Senior Advisor in Reimbursement & Market Access at TTi Health Research & Economics.
Greg holds a MBA in Business and Administration and Management from Rensselaer Polytechnic Institute at Hartford.
Avijeet Chopra, Ph.D., MBA is an experienced Global Health Economics and Outcomes Researcher with expertise in health economic modeling, indirect treatment comparisons using meta-analysis, and systematic reviews. He has an extensive background in clinical and translational sciences and analytical research with experience in synthesizing, implementing, and communicating scientific evidence through peer-reviewed publications and user interfaces, in respect to the healthcare landscape and need for pharmaceutical drugs, biotechnology, and medical devices. He serves as HEOR Senior Associate at TTi Health Research & Economics.
Avi holds a Ph.D. in Clinical & Translational Sciences from The University of Connecticut and is a Health Economics Fellow from the University of York.